#77 Strong Clinical Relevance
High-quality evidence with meaningful patient or clinical significance.
Clinicians treating older adults need to understand cannabis use patterns in this population because rising consumption may interact with age-related polypharmacy, cognitive decline, and fall risk. This guide provides practical information that clinicians can discuss with patients considering or currently using cannabis, enabling informed shared decision-making about safety, drug interactions, and appropriate dosing for older adults. Awareness of cannabis popularity among seniors helps clinicians identify a previously underrecognized substance use exposure that warrants screening and counseling in routine geriatric care.
Cannabis use among adults aged 50 and older has increased substantially, with 21% reporting use in 2024 according to University of Michigan data, reflecting a significant shift in consumption patterns within this demographic. This rise in older adult cannabis use has important clinical implications, as seniors may have different pharmacokinetics, comorbidities, and polypharmacy considerations that affect safety and efficacy compared to younger users. Clinicians should be prepared to assess cannabis use in their older patients through routine screening, as many may be self-treating conditions such as chronic pain, insomnia, or anxiety without medical supervision or discussion with their healthcare providers. Understanding the legal landscape in states like Minnesota, where cannabis is now accessible, helps clinicians provide evidence-based guidance on safe use patterns, potential drug interactions, and alternatives when appropriate. Given the rapid expansion of cannabis availability and use in older populations, clinicians should develop competency in cannabis counseling specific to aging patients, including dosing considerations and monitoring for adverse effects such as falls or cognitive changes. Clinicians caring for older adults should proactively discuss cannabis use during history taking and educate patients about evidence-based risks and benefits relevant to their specific health conditions and medication regimens.
“We’re seeing increased cannabis use in older adults, and while observational data like the Michigan study show the trend is real, we still lack robust clinical trials in this population to guide dosing, drug interactions, and long-term safety. What I tell my older patients is that the early signals suggest potential benefit for certain conditions like chronic pain and sleep, but we need to approach this thoughtfully, starting low and going slow, while monitoring carefully for falls, cognitive effects, and interactions with their other medications.”
🧓 As cannabis legalization expands across the United States, clinicians should recognize that older adults represent a rapidly growing demographic of users, with prevalence approaching one in five adults aged 50 and older. While some older patients may use cannabis for legitimate symptom management—particularly for pain, insomnia, or chemotherapy-related side effects—the evidence base for efficacy in this population remains limited and heterogeneous, and educational materials like state-sponsored guides may inadvertently normalize use without adequate discussion of risks. Older adults face particular vulnerabilities including polypharmacy interactions, altered pharmacokinetics, increased fall risk, cognitive effects, and potential drug-drug interactions with common medications like warfarin or benzodiazepines, yet many may not disclose use to their physicians. Clinicians should routinely ask about cannabis use as part of medication reconciliation, counsel patients about evidence gaps and individual risk factors, and document use
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
